Aptevo Therapeutics Inc. shares surged nearly 50% early Thursday on promising leukemia trial results, before paring gains in ...

SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on ...

Aptevo Therapeutics (APVO) announced 100% of patients achieved remission within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid ...

EST Aptevo Therapeutics (APVO) trading halted, volatility trading pausePick the best stocks and maximize your portfolio:Discover ...

Two of three patients achieved both complete remission and MRD-negative status High response rates observed in earlier studies continue in ongoing mipletamig trial Cohort 2 enrollment commencing ...

SEATTLE, WA / ACCESSWIRE / November 29, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), today announced that it will conduct a reverse stock split of its outstanding ...

Ladenburg Thalmann has recently initiated Aptevo Therapeutics Inc (APVO) stock to Buy rating, as announced on November 5, 2018, according to Finviz. Analyst ratings are significant because they ...

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a report issued on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

Ladenburg Thalmann has recently initiated Aptevo Therapeutics Inc (APVO) stock to Buy rating, as announced on November 5, 2018, according to Finviz. Analyst ratings are significant because they ...

Aptevo Therapeutics (APVO) announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-37. The Reverse Stock Split is expected to become ...